Chronic Periodontitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

Chronic Periodontitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Chronic Periodontitis Pipeline Insights 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Chronic Periodontitis pipeline landscape. It covers the Chronic Periodontitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Periodontitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Periodontitis Pipeline Report

  • DelveInsight’s Chronic Periodontitis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Chronic Periodontitis treatment.
  • The leading companies working in the Chronic Periodontitis Market include Amyndas Pharmaceuticals, Takeda, CSL behring, Vaxcyte, Noveome, Perioc, and others.
  • Promising Chronic Periodontitis Pipeline Therapies in the various stages of development include ALH-L1005 600mg/day, Probiotic, Inersan, Doxycycline, YH14642 500mg Tab, and others.
  • May 2023: Biolase Inc. announced a study of Phase 1 clinical trials for HP and Epic Diode. The primary aim of this pilot study is to determine whether the test methods described feasibly achieve the goal defined for a future clinical study. The purpose is a quantitative assessment of the bactericidal effect of two adjunctive treatments compared to that of conventional periodontal maintenance debridement.

 

Request a sample and discover the recent advances in Chronic Periodontitis Treatment Drugs @ Chronic Periodontitis Pipeline Report

 

In the Chronic Periodontitis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Chronic Periodontitis NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Chronic Periodontitis Overview

Periodontal disease and dental caries are the most common diseases in the oral cavity. Chronic periodontitis is one of the periodontal diseases. It is a long-lasting inflammatory disease affecting the soft and hard tissues around the teeth and it is common worldwide. This disease is related to common and preventable biological risk factors (e.g., high blood pressure, high blood cholesterol, diabetes, genetic factors, and obesity) and behavioral risk factors (e.g., an unhealthy diet, physical inactivity, and tobacco use). Chronic periodontitis is ideally diagnosed at the beginning of the disease.

 

Find out more about Chronic Periodontitis Therapeutics Assessment @ Chronic Periodontitis Preclinical and Discovery Stage Products

 

Chronic Periodontitis Emerging Drugs Profile

  • ST 266: Noveome

 

Chronic Periodontitis Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the Chronic Periodontitis therapies. The Chronic Periodontitis companies which have their Chronic Periodontitis drug candidates in the most advanced stage, i.e. Phase II include, Noveome.

 

DelveInsight’s Chronic Periodontitis Pipeline Report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Chronic Periodontitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

 

Chronic Periodontitis Pipeline Products have been categorized under various Molecule types such as

  • Peptide
  • Protein
  • Propylene glycols
  • Cell Therapy

 

Learn more about the emerging Chronic Periodontitis Pipeline Therapies @ Chronic Periodontitis Clinical Trials Assessment

 

Scope of the Chronic Periodontitis Pipeline Report

  • Coverage- Global
  • Chronic Periodontitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Chronic Periodontitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Chronic Periodontitis Companies- Amyndas Pharmaceuticals, Takeda, CSL behring, Vaxcyte, Noveome, Perioc, and others.
  • Chronic Periodontitis Pipeline Therapies- ALH-L1005 600mg/day, Probiotic, Inersan, Doxycycline, YH14642 500mg Tab, and others.

 

Dive deep into rich insights for new drugs for Chronic Periodontitis Treatment, Visit @ Chronic Periodontitis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Periodontitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Periodontitis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase II)
  8. Ciclosporin topical gel: Perioc
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase I/II)
  11. Drug name: Company name
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. VAX PG: Vaxcyte
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Chronic Periodontitis Key Companies
  24. Chronic Periodontitis Key Products
  25. Chronic Periodontitis- Unmet Needs
  26. Chronic Periodontitis- Market Drivers and Barriers
  27. Chronic Periodontitis- Future Perspectives and Conclusion
  28. Chronic Periodontitis Analyst Views
  29. Chronic Periodontitis Key Companies
  30. Appendix

 

For further information on the Chronic Periodontitis Pipeline therapeutics, reach out to Chronic Periodontitis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-periodontitis-market